Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh, Pittsburgh, PA, United States.
Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh, Pittsburgh, PA, United States.
Curr Opin Immunol. 2014 Jun;28:84-9. doi: 10.1016/j.coi.2014.02.002. Epub 2014 Mar 15.
Multidrug resistant (MDR) Gram negative bacterial infections are increasing in frequency and are associated with significant financial costs, morbidity and mortality. Current antibiotic therapies are associated with unacceptably poor clinical outcomes and toxicity. Unfortunately, the development of novel antimicrobials is stagnant leaving a significant clinical need for alternative treatments of MDR Gram negative rod infections. Recent preclinical studies have identified Th17 cells as critical mediators of broadly protective adaptive immunity, including protection against MDR infections. Studies of Th17 eliciting antigens, adjuvants and routes of immunization have identified potential vaccine strategies that may confer long-lived adaptive immunity against MDR Gram negative bacterial infections.
多重耐药（MDR）革兰氏阴性菌感染的频率正在增加，并与重大的财务成本、发病率和死亡率相关。目前的抗生素治疗与不可接受的不良临床结果和毒性相关。不幸的是，新型抗菌药物的开发停滞不前，因此迫切需要替代治疗方法来治疗 MDR 革兰氏阴性杆菌感染。最近的临床前研究已经确定 Th17 细胞是广泛保护性适应性免疫的关键介质，包括对 MDR 感染的保护。对 Th17 诱导抗原、佐剂和免疫途径的研究已经确定了潜在的疫苗策略，这些策略可能对 MDR 革兰氏阴性细菌感染提供长期的适应性免疫。
